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Introduction
First-trimester maternal serum pregnancy-associated
plasma protein-A (PAPP-A) has been reported to be an
important biochemical marker in prenatal screening of
fetal Down syndrome [1,2]. PAPP-A is produced by
syncytiotrophoblast of placenta and has been identified
as a protease for insulin-like growth factor binding
protein (IGFBP)-4 [3]. Therefore, pregnancies with low
maternal levels of PAPP-A would expect to have low
levels of insulin-like growth factor (IGF), which plays 
a key role in regulating fetal growth [4,5]. In addition
to the fetal growth restriction, several reports demon-
strated that low maternal serum PAPP-A levels were
associated with adverse pregnancy outcomes, such as
miscarriage, preeclampsia, and stillbirth [6–11]. Accord-
ing to the most recent study by Smith et al, low con-
centrations of PAPP-A during the first trimester were
associated with an earlier onset of spontaneous labor
at full term [11]. Whether low maternal serum PAPP-A
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SUMMARY
Objective: To assess the relationship between the first-trimester maternal serum pregnancy-associated plasma
protein-A (PAPP-A) levels and pregnancies complicated by preterm delivery.
Materials and Methods: The correlation between PAPP-A levels and gestational age at delivery was analyzed by
linear regression. The probabilities of low PAPP-A multiples of the median (MoM) levels between preterm deliv-
ery and control population were analyzed by logit model.
Results: A positive correlation was noted between the first-trimester PAPP-A MoM levels and gestational age at
delivery between 34–38 weeks (p < 0.001). Lower PAPP-A MoM level had a significantly higher likelihood of
preterm delivery (p < 0.05). When preterm premature rupture of membranes (PPROM) and preterm labor (PTL)
were analyzed separately, there was an increasing likelihood of PPROM with decreasing PAPP-A MoM levels (p <
0.05), but not for PTL with intact membranes.
Conclusion: Low maternal serum PAPP-A levels during the first trimester may reflect a trophoblast invasion
defect in the maternal–fetal interface, resulting in subsequent preterm delivery, particularly in those of PPROM.
[Taiwan J Obstet Gynecol 2007;46(3):242–247]
Key Words: pregnancy-associated plasma protein-A, preterm delivery, preterm labor, preterm premature 
rupture of membranes
*Correspondence to: Dr Ming-Song Tsai, Prenatal Diagnosis Center,
Department of Obstetrics and Gynecology, Cathay General
Hospital, 280 Jen-Ai Road, Section 4, Taipei 106, Taiwan.
E-mail: mstsai@cgh.org.tw
Accepted: December 11, 2006
Taiwan J Obstet Gynecol • September 2007 • Vol 46 • No 3 243
PAPP-A in Pregnancies with Preterm Delivery
levels are related to pregnancies complicated by preterm
delivery is still uncertain [7–11]. Moreover, the relation-
ship between maternal PAPP-A level and preterm pre-
mature rupture of membranes (PPROM) has not been
previously reported. Recent reports suggest that there
may be different pathophysiologic pathways in placen-
tation determining the progression to PPROM and
preterm labor (PTL) [12–14]. The aim of this study was
to assess the relationship between low maternal serum
PAPP-A levels during the first trimester and pregnancies
complicated by PTL and PPROM.
Materials and Methods
This retrospective clinical study was carried out on 2,621
women with singleton pregnancies who had under-
gone the first-trimester Down syndrome screening and
delivered their babies in our hospital. The screening
protocol included the measurement of fetal nuchal
translucency thickness, maternal serum levels of free 
β-hCG, as well as PAPP-A, at 10–13 weeks of gestation
and was optionally implemented on pregnant women
who came to our hospital for prenatal care [15,16].
Their medical records were reviewed, and data on the
pregnancies complicated with adverse pregnancy out-
comes were abstracted, including spontaneous abor-
tion, abruptio placentae, abnormal fetal karyotype,
congenital fetal anomaly, intrauterine fetal death,
intrauterine growth restriction, pregnancy-associated
hypertensive disorder, placenta previa, PPROM, PTL,
gestational diabetes mellitus, glucose intolerance, and
maternal hyperthyroidism. Gestational age was deter-
mined by ultrasound of the fetal crown–rump length
at the time of nuchal translucency measurement. PTL
was defined as any spontaneous delivery before 37
completed weeks of gestation without rupture of mem-
branes. PPROM was diagnosed by sterile speculum
examination that confirmed fluid pooled in the vagina
and positive nitrazine testing before onset of PTL.
PAPP-A levels were divided by their day-specific
median levels to determine the multiples of the median
(MoM) using Alpha software (Logical Medical Systems,
UK) based on a multivariate Gaussian distribution as
described by Wald and Hackshaw [17]. The correla-
tion between maternal serum PAPP-A MoM levels at
10–13 weeks and gestational age at the time of deliv-
ery was analyzed. The probabilities of low PAPP-A
MoM levels between the preterm delivery and control
populations were compared. Among the preterm deliv-
ery, PTL and PPROM were further analyzed. This study
was approved by our hospital’s Institutional Review
Board.
Statistical analysis
Linear regression analysis was performed to evaluate
the relationship between the PAPP-A MoM levels and
gestational age at delivery. The PAPP-A MoM levels were
divided into eight parts with increment of 0.3 MoM.
The frequencies of PPROM, PTL, preterm delivery, and
control population were calculated and are shown in
Table 2. The frequencies of PPROM and control had a
binomial distribution. Then, the logit model (model 1:
log(pi/qi) = α + β × i; and model 2: log(pi/qi) = α) was used
to fit the data. The goodness of fit and the significant
trend for preterm delivery-related PAPP-A parts were
assessed by using maximum likelihood estimator. The
likelihood ratio of chi-square G2 (M) was obtained in the 
model: where nij = obser-
vations, and mij = estimates under the model. A p value
of less than 0.05 was considered statistically signifi-
cant. G21 was the difference between G2 (M2) and G2
(M1)(G2 (M2) − G2 (M1) = G21). Then, G21 was used to
test for β = 0. When G21 > 3.841 is significant at the
p = 0.05 level, model 1 will be used. The odds ratio,
OR = exp(b), will be calculated. For a unit change in
PAPP-A MoM levels, the estimated odds of adverse
outcome are multiplied by OR.
Results
Among the 2,621 pregnancies, we excluded 60 pregnan-
cies complicated with spontaneous abortion (8 cases),
abnormal fetal karyotype (17 cases), fetal structural
anomalies (23 cases), and intrauterine fetal death (12
cases). A total of 2,561 pregnancies were enrolled into
this study, which consisted of 189 pregnancies with
preterm delivery (44 with PPORM and 145 with PTL) and
2,372 controls with spontaneous deliveries after 37
weeks of gestation. The median PAPP-A MoM level of
these 2,561 pregnancies was 1.04. There were no sta-
tistical differences between the preterm delivery popu-
lation and the control population in maternal age
(29.6 ± 3.6 vs. 29.7 ± 3.5 years), maternal weight (54.9 ±
8.2 vs. 54.5 ± 7.7 kg) and CRL at the time of Down syn-
drome screening (54.3 ± 10.5 vs. 54.4 ± 9.9 mm).
The median and the mean of PAPP-A MoM levels
during the first trimester increased with higher gesta-
tional age at delivery between 34–38 weeks of gestation,
and then declined slowly afterward as shown in Table 1.
The association between maternal serum PAPP-A MoM
level at 10–13 gestational weeks and gestational age 
at delivery was examined by linear regression analysis.
There was a significant positive correlation in those
women who gave birth between 34–38 weeks of 
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gestation. The Figure shows a plot of gestational age
at delivery on the x-axis and PAPP-A MoM level at
10–13 weeks of gestation on the y-axis, along with 
the regression line. The regression equation was Y =
−27.059 + 1.4697 × X1 − 0.0191 × X2 (t value for inter-
cept, X, and X2 were − 79.61, 19.15, and −82.01,
respectively; p < 0.001).
When the probability of preterm delivery was com-
pared among the eight PAPP-A MoM parts using logit
model analysis, the lowest part of PAPP-A MoM level
had the highest probability of preterm delivery, and the
statistics was significant (likelihood ratio chi-square,
G21 = 7.59; p < 0.05). When we segregated the preterm
deliveries into two groups, PPROM and PTL, there was
a significant trend in that probabilities of PPROM
were increasing while PAPP-A MoM levels were decreas-
ing (likelihood ratio chi-square, G21 = 6.77; p < 0.05).
However, the PTL group (likelihood ratio chi-square,
G21 = 3.20; p > 0.05) was not influenced, as shown in
Table 2.
Among the 189 pregnancies of preterm delivery, 35
pregnancies were complicated by other adverse out-
comes simultaneously, including 18 with pregnancy-
induced hypertensive disorders, 11 with gestational
diabetes mellitus, one with placental previa, three with
abruptio placentae, and two with maternal hyperthy-
roidism. The rest of the 154 pregnancies did not have
any other adverse outcomes. These 154 pregnancies (44
PPROM and 110 PTL) were compared with 1,813 nor-
mal pregnancies from the 2,372 control population,
which excluded 559 pregnancies complicated with
abruptio placentae (3 cases), intrauterine growth restric-
tion (180 cases), pregnancy-associated hypertensive
disorder (183 cases), placenta previa (18 cases), fetal
macrosomia (59 cases), gestational diabetes melli-
tus (47 cases), glucose intolerance (59 cases), and
maternal hyperthyroidism (10 cases). Logit model 
was used to analyze the data. There were significant
trends for increased probability of PPROM, PTL, and
preterm delivery with decreasing PAPP-A MoM levels
(likelihood ratio chi-square G21 for PPROM, PTL, and
preterm delivery were 7.85, 6.13, and 12.34, respec-
tively; p < 0.05).
Discussion
In this study, we demonstrated that a significant trend
of which the decreased PAPP-A MoM level in the first
trimester would increase probability of pregnancy
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Figure. Gestational age at time of delivery plotted against pregnancy-associated plasma protein-A (PAPP-A) multiples of
median (MoM) level from a linear regression analysis. L95% = lower limit with 95% confidence interval; pred value = predictive
value; U95% = upper limit with 95% confidence interval.
Table 1. The mean and median maternal serum pregnancy-associated plasma protein-A (PAPP-A) multiples of median 
(MoM) levels during the first trimester of each gestational age at delivery during 34–41 weeks
PAPP-A MoM
Gestational age (wk) 34 35 36 37 38 39 40 41
Number of cases 14 48 87 269 671 860 477 95
Mean 0.76 0.94 0.98 1.11 1.18 1.11 1.10 1.06
Median 0.72 0.91 0.92 0.99 1.05 1.00 0.99 0.89
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complicated by preterm delivery before 37 weeks of
gestation, particularly for those women with PPROM.
Our data revealed that a 0.3 PAPP-A MoM increase
during the first trimester was associated with an 85%
reduction in the likelihood of pregnancy complicated
by subsequent preterm delivery.
This finding is consistent with a recent report pre-
sented by Smith et al, which described that the maternal
serum PAPP-A in the lowest fifth percentile at 8–14
weeks had an increasing risk of extremely premature
delivery (24–32 weeks; odds ratio, 2.9) and moderately
premature delivery (33–36 weeks; odds ratio, 2.4)
[10]. Furthermore, we found that this relationship was
stronger in pregnancies with PPROM than those of
PTL with intact membranes. Nevertheless, according to
another report by the same author, lower concentra-
tions of PAPP-A in the first trimester were associated
with an earlier onset of spontaneous labor at full term
[11], which was not quite the same as our observation
in this study. We found the trend of lower PAPP-A lev-
els at 10–13 weeks of gestation and of earlier onset of
labor in those women who gave birth between 34–38
weeks of gestation. In contrast, the maternal PAPP-A
levels declined when women gave birth after 38 weeks
of gestation. The causes of this discrepancy might be
due to the different races and very light smoking behav-
ior [18] of our study population or some other factors
yet to be identified.
Preterm delivery is the major cause of neonatal mor-
tality and morbidity. The etiology of PTL and PPROM is
multifactorial [19]. Most of the causes are still uncertain.
It has been known for a long time that infection of the
intra-amniotic cavity with elevation of inflammatory
cytokines plays an important role for those women
complicated by PTL and PPROM [20,21]. However,
not all pregnant women with preterm delivery have an
evidence of infection. Therefore, some pathophysiologic
processes other than infection should be involved in
causing preterm delivery [20,21]. The following recent
reports have indicated that vascular developmental
defects in placentation may play a role in the pathogene-
sis of preterm delivery, especially in those with PPROM
[22,23]. Arias et al reported that maternal placental vas-
culopathy and infection were identified among those
with pregnancies complicated by PTL as well as PPROM
[22]. Kim et al reported that the failure of physiologic
transformation in the myometrial segments of the spiral
arteries was frequent in pregnancy with PPROM [23].
The IGF family is believed to be important in implan-
tation and placental physiology [24]. PAPP-A recently
has been identified as an IGFBP-4 protease, and the
IGFBP-4 is the second most abundant IGFBP in the
placental bed. At the maternal–fetal interface, PAPP-A
proteolyze IGFBP-4 and thus increase IGF bioavailabil-
ity locally in the placenta to promote IGF-2-mediated
trophoblast invasion into maternal deciduas and to
modulate IGF regulation of steroidogenesis and glucose
and amino acid transport in the villus [24,25]. In human
pregnancy, the elevated levels of PAPP-A and IGFBP-4
proteolysis are normally detected in the maternal cir-
culation in early gestation. Therefore, low maternal
serum PAPP-A levels in the first trimester are supposed
Table 2. Frequency data of each study group related to eight pregnancy-associated plasma protein-A (PAPP-A) multiples of 
median (MoM) level parts and statistical data of logit model analysis
PAPP-A PPROM PTL PTD Control
MoM (n = 44) (n = 145) (n = 189) (n = 2,372)
≤ 0.3 3 12 15 116
0.31–0.60 15 27 42 424
0.61–0.90 8 30 38 479
0.91–1.20 7 33 40 441
1.21–1.50 5 18 23 343
1.51–1.80 3 7 10 216
1.81–2.10 2 5 7 160
> 2.10 1 13 14 193
Logit model
Model 1 Model 2 Test β = 0
α β G26 α G27 G21
PPROM – Control −3.15 −0.22 2.28 −3.98 9.05 6.77*
PTL – Control −2.47 −0.08 7.25 −2.79 10.45 3.20
PTD – Control −2.09 −0.11 4.50 −2.53 12.09 7.59*
*Statistically significant. PTD = preterm delivery; PTL = preterm labor; PPROM = preterm premature rupture of membranes.
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to be an early sign of placentation defect during the
implantation processes.
Based on the aforementioned reports, the possible
mechanism linking the low maternal serum PAPP-A level
during the first trimester to subsequent preterm delivery
may be vascular developmental defects in placentation.
In addition, our study indicated that the association
between low PAPP-A and PPROM seems to be stronger
than that between low PAPP-A and PTL, which suggests
that the vasculopathy in placentation in these two enti-
ties may be somewhat different in severity. Furthermore,
Fortunato et al recently demonstrated that there were
distinct molecular pathways that determined the pro-
gression to PPROM or PTL [13,14]. It would be impor-
tant to determine whether PPROM and PTL have a
vascular insult in placentation processes of early preg-
nancy and whether a secondary insult of infection
occurs later. Consequently, an elevation of inflamma-
tory cytokines induces prostaglandin production and
leads to the cervical ripening as well as prostaglandin-
mediated uterine contractility.
In summary, two interesting observations were made
in this study. First, the lower maternal PAPP-A levels were
associated with the earlier onset of labor at 34–38
weeks of gestation. Second, there was a significant trend
in that decreased PAPP-A MoM levels during the first
trimester would increase the likelihood of pregnancy
complicated by preterm delivery, particularly for those
women with PPROM. We postulate that maternal serum
PAPP-A levels during the first trimester might represent
a condition of trophoblast invasion processes in the
maternal–fetal interface, which is one of the important
factors for regulating placental growth and determining
the time of onset of labor.
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